Stock analysis, AI verdict, fundamentals & technical signals
Rating: HOLD AI Verdict: HOLD
Price: $1417.99 Analyst target: $1397.02 Upside: -1.48%
LLY is in a strong uptrend (close 1273.72 vs SMA50 1081 and SMA200 782, ADX 55) with a bullish catalyst flow of analyst target raises (Goldman 1,413, Barclays 1,400) and the Mubadala manufacturing deal, supported by 47.7% revenue growth and a 33.5% margin. However, it is extended after a run to a 52-week high of 1321, with CCI 221.7 and price at the upper Bollinger band (1270) just below 3-month resistance of 1292.65, and the weekly bar reversed from the 1321 high, so this is a poor entry point rather than a dip buy.
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
See the full interactive analysis & chart →Informational only — not investment advice.